Status:
RECRUITING
Neurocognitive Outcomes for ICU Patients With Acute Kidney Injury
Lead Sponsor:
Dr. Gordon Boyd
Conditions:
Delirium
Acute Kidney Injury
Eligibility:
All Genders
18+ years
Brief Summary
Introduction. Initiation of acute kidney replacement therapy (KRT) is common in critically ill adults admitted to the intensive care unit (ICU), and is associated with increased morbidity and mortalit...
Eligibility Criteria
Inclusion
- age greater than or equal to 18 years
- admitted to the Kingston Health Sciences Intensive Care Unit
- diagnosis of severe AKI requiring Kidney Replacement Therapy (KRT) (defined by the presence of either a twofold increase in serum creatinine from baseline, serum creatinine level greater than or equal to 354 micromol/L with an increase of 27 micromol/L from baseline, or urine output \<6 mL/kg in the preceding 12 hours)
- within 12 hours of initiation of KRT via intermittent hemodialysis (iHD) or continuous kidney replacement therapy (CKRT).
Exclusion
- acquired or congenital neurological disorders
- any contraindication to testing with cerebral oximetry, Kinarm, or MRI (e.g., claustrophobia, limb amputation, paresis, neuromuscular disorders, etc.)
- KRT via PD
- failure to consent
- life expectancy less than 24 hours
- clinical suspicion of renal obstruction
- rapidly progressive glomerulonephritis or interstitial nephritis
- prehospitalization eGFR \<30 mL/min/1.73m2.
Key Trial Info
Start Date :
January 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2027
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT04722939
Start Date
January 15 2021
End Date
January 1 2027
Last Update
December 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kingston Health Sciences Centre
Kingston, Ontario, Canada, K7L3C9